Carillon Tower Advisers Inc. Has $6.34 Million Holdings in Balchem Co. (BCPC)

Carillon Tower Advisers Inc. boosted its stake in Balchem Co. (NASDAQ:BCPC) by 2.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,558 shares of the basic materials company’s stock after buying an additional 1,093 shares during the period. Carillon Tower Advisers Inc.’s holdings in Balchem were worth $6,340,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. grew its stake in shares of Balchem by 9.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 6,572 shares of the basic materials company’s stock worth $646,000 after purchasing an additional 589 shares in the last quarter. Piedmont Investment Advisors LLC grew its stake in shares of Balchem by 9.3% in the second quarter. Piedmont Investment Advisors LLC now owns 7,482 shares of the basic materials company’s stock worth $734,000 after purchasing an additional 635 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Balchem by 15.9% in the second quarter. Victory Capital Management Inc. now owns 6,316 shares of the basic materials company’s stock worth $620,000 after purchasing an additional 865 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Balchem by 13.2% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,690 shares of the basic materials company’s stock worth $862,000 after purchasing an additional 898 shares in the last quarter. Finally, Scout Investments Inc. grew its stake in shares of Balchem by 2.1% in the third quarter. Scout Investments Inc. now owns 59,871 shares of the basic materials company’s stock worth $6,711,000 after purchasing an additional 1,247 shares in the last quarter. 88.17% of the stock is owned by institutional investors.

In other news, Director Daniel E. Knutson bought 650 shares of the firm’s stock in a transaction that occurred on Tuesday, November 13th. The stock was acquired at an average price of $89.11 per share, with a total value of $57,921.50. Following the completion of the purchase, the director now directly owns 1,495 shares of the company’s stock, valued at approximately $133,219.45. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.02% of the company’s stock.

BCPC has been the subject of several recent analyst reports. Sidoti raised Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price target for the company in a research note on Tuesday, October 16th. HC Wainwright initiated coverage on Balchem in a research note on Tuesday, September 25th. They issued a “buy” rating for the company. BidaskClub cut Balchem from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 29th. ValuEngine raised Balchem from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, Pivotal Research raised Balchem from a “hold” rating to a “buy” rating and increased their price target for the stock from $95.00 to $100.00 in a research note on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $122.33.

NASDAQ:BCPC opened at $86.70 on Monday. Balchem Co. has a 1 year low of $70.23 and a 1 year high of $117.79. The firm has a market capitalization of $2.80 billion, a PE ratio of 29.59 and a beta of 0.95. The company has a quick ratio of 2.33, a current ratio of 3.42 and a debt-to-equity ratio of 0.27.

Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Tuesday, November 6th. The basic materials company reported $0.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.12. Balchem had a return on equity of 14.51% and a net margin of 15.67%. The company had revenue of $155.04 million during the quarter, compared to analysts’ expectations of $163.66 million. During the same quarter in the prior year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. As a group, sell-side analysts predict that Balchem Co. will post 2.45 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.com-unik.info/2018/12/03/carillon-tower-advisers-inc-has-6-34-million-holdings-in-balchem-co-bcpc.html.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Recommended Story: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).

Institutional Ownership by Quarter for Balchem (NASDAQ:BCPC)

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit